131 related articles for article (PubMed ID: 2608022)
1. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion].
Suzuki H
Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1922-31. PubMed ID: 2608022
[TBL] [Abstract][Full Text] [Related]
2. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
3. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
[TBL] [Abstract][Full Text] [Related]
4. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
5. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
Suzuki H; Abo S; Kitamura M; Hashimoto M; Izumi K
Surg Today; 1993; 23(12):1053-9. PubMed ID: 8118118
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
7. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
8. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
[TBL] [Abstract][Full Text] [Related]
9. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
10. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
11. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of malignant pleural effusion].
Takada M; Fukuoka M
Gan To Kagaku Ryoho; 1989 Feb; 16(2):165-72. PubMed ID: 2493220
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with malignant pleural effusions due to advanced lung cancer by transfer of autologous LAK cells combined with rIL-2 or rIL-2 alone.
Li D; Wang Y; Yao X; Shao J; Chen Y; Ba D
Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):51-5. PubMed ID: 2371266
[No Abstract] [Full Text] [Related]
14. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
15. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
[TBL] [Abstract][Full Text] [Related]
16. [Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells].
Kikuchi Y; Oomori K; Miyauchi M; Kita T; Kuki E; Iwano I; Hirata J; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1891-5. PubMed ID: 2592812
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
18. [Intrapleural administration of recombinant interleukin-2 in a patient with pleural effusion due to non-Hodgkin's lymphoma].
Kojiro N; Ishihara H; Ito M; Nishiki M; Yamashita K; Onoshi M
Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Aug; 27(8):954-9. PubMed ID: 2615111
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]